We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$269M
1-Year Est. Return
103.38%
This Fund
S&P 500
This Quarter
Est. Return
-2.44%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$35.6M
(-13%)
Cap. Flow
-$7.85M
Cap. Flow
% of AUM
-3.15%
Top 10 Holdings %
Top 10 Hldgs %
65.95%
Holding
50
New
11
Increased
8
Reduced
11
Closed
14
Avg Time Held Equity + Options
3.7
quarters
Top 10 Avg Time Held Equity + Options
3
quarters
Top 20 Avg Time Held Equity + Options
3.5
quarters
Avg Time Held Equity only
3.9
quarters
Top 10 Avg Time Held Equity only
3
quarters
Top 20 Avg Time Held Equity only
3.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$15.7M |
| 2 |
Vor Biopharma
VOR
|
+$9.87M |
| 3 |
Celldex Therapeutics
CLDX
|
+$9M |
| 4 |
Xeris Biopharma Holdings
XERS
|
+$7.43M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$7.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
aTyr Pharma
ATYR
|
+$13.6M |
| 2 |
Cytokinetics
CYTK
|
+$12.4M |
| 3 |
CG Oncology
CGON
|
+$11.3M |
| 4 |
Replimune Group
REPL
|
+$10.8M |
| 5 |
Definium Therapeutics
DFTX
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.07% |
| 2 | Miscellaneous | 1.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Delcath Systems
DCTH
$532M
| $30.6M | 12.31% |
3,300,389
| – | – |
2023 Q4
9 quarters
|
|
|
2
Xeris Biopharma Holdings
XERS
$1.86B
| $18.7M | 7.53% |
3,231,700
+1,120,000
| +53% | +$7.43M |
2023 Q4
9 quarters
|
|
3
Fennec Pharmaceuticals
FENC
$357M
| $17.9M | 7.19% |
2,908,201
+294,693
| +11% | +$2.28M |
2024 Q4
5 quarters
|
|
4
Savara
SVRA
$982M
| $17.5M | 7.03% |
3,203,721
-200,000
| -6% | -$1.11M |
2024 Q4
5 quarters
|
|
|
5
Vaxcyte
PCVX
$10.4B
| $16.9M | 6.77% |
+290,000
| New | +$15.7M |
2026 Q1
0 quarters
|
|
6
EyePoint Inc
EYPT
$265M
| $13.4M | 5.37% |
1,036,737
+346,737
| +50% | +$5.18M |
2025 Q3
2 quarters
|
|
7
X4 Pharmaceuticals
XFOR
$258M
| $13.3M | 5.33% |
3,214,766
+608,846
| +23% | +$2.28M |
2025 Q3
2 quarters
|
|
|
8
Vor Biopharma
VOR
$1.13B
| $12.5M | 5.02% |
+700,000
| New | +$9.87M |
2026 Q1
0 quarters
|
|
9
MediWound
MDWD
$158M
| $12.1M | 4.85% |
749,054
| – | – |
2023 Q4
9 quarters
|
|
10
Verastem
VSTM
$675M
| $11.3M | 4.55% |
2,138,475
+350,000
| +20% | +$2.16M |
2024 Q4
5 quarters
|
|
|
11
Celldex Therapeutics
CLDX
$2.22B
| $10.5M | 4.21% |
+330,000
| New | +$9M |
2026 Q1
0 quarters
|
|
|
12
BioCryst Pharmaceuticals
BCRX
$2.06B
| $8.79M | 3.53% |
+923,057
| New | +$7.17M |
2026 Q1
0 quarters
|
|
|
HELP
13
Helus Pharma Inc. Common Stock
HELP
$767M
| $7.35M | 2.95% |
1,531,814
-125,726
| -8% | -$813K |
2024 Q1
8 quarters
|
|
|
14
CG Oncology
CGON
$5.53B
| $6.77M | 2.72% |
100,000
-200,000
| -67% | -$11.3M |
2025 Q2
3 quarters
|
|
15
InspireMD
NSPR
$23.4M
| $6.37M | 2.56% |
3,905,743
| – | – |
2023 Q4
9 quarters
|
|
16
Atea Pharmaceuticals
AVIR
$399M
| $6.3M | 2.53% |
+1,171,855
| New | +$5.38M |
2026 Q1
0 quarters
|
|
17
Profound Medical
PROF
$256M
| $5.37M | 2.16% |
828,118
-240,837
| -23% | -$1.66M |
2023 Q4
9 quarters
|
|
18
Viridian Therapeutics
VRDN
$2.06B
| $4.9M | 1.97% |
250,401
-199,599
| -44% | -$5.93M |
2025 Q1
4 quarters
|
|
|
19
CALL
Replimune Group
REPL
$1.14B
| $2.75M | 1.1% |
1,275,600
+1,044,700
| +452% | +$7.99M |
2025 Q2
3 quarters
|
|
20
PolyPid
PYPD
$99.1M
| $2.62M | 1.05% |
597,926
-98,630
| -14% | -$436K |
2024 Q1
8 quarters
|
|
21
Myomo
MYO
$51.1M
| $2.6M | 1.04% |
3,847,272
+7,500
| +0.2% | +$6.15K |
2023 Q4
9 quarters
|
|
22
Talphera
TLPH
$55.5M
| $2.51M | 1.01% |
3,353,916
-225,357
| -6% | -$204K |
2023 Q4
9 quarters
|
|
23
Ovid Therapeutics
OVID
$428M
| $2.46M | 0.99% |
+1,107,994
| New | +$1.98M |
2026 Q1
0 quarters
|
|
|
24
Definium Therapeutics
DFTX
$4.62B
| $2.36M | 0.95% |
125,000
-625,000
| -83% | -$10.6M |
2025 Q1
4 quarters
|
|
25
OnKure Therapeutics
OKUR
$95.2M
| $1.84M | 0.74% |
443,763
-286,725
| -39% | -$885K |
2025 Q4
1 quarter
|
|
Similar funds
GPFA
TW
PM
ZEP
LBW
VP
5W
NF
Rosalind Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Rosalind Advisors held 50 positions worth $249M, down 13% from $285M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Rosalind Advisors withdrew a net $7.85M in Q1 2026, closing 14 positions and reducing 11 holdings. Its most notable exit was aTyr Pharma, an estimated $13.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous.
Against the trend, Rosalind Advisors opened a new position in Vaxcyte worth $16.9M.
- Rosalind Advisors's largest Q1 2026 buy was Vaxcyte: 290,000 shares worth $16.9M.
- Rosalind Advisors added most to Xeris Biopharma Holdings in Q1 2026, an estimated $7.43M increase.
- Rosalind Advisors's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $11.3M.
- Rosalind Advisors fully exited aTyr Pharma in Q1 2026, selling an estimated $13.6M.
- Rosalind Advisors's ten largest holdings make up 66% of its $249M portfolio in Q1 2026.
- Rosalind Advisors opened 11 new positions and closed 14 in Q1 2026.
- Rosalind Advisors's portfolio value fell 13% quarter-over-quarter to $249M.
Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.